User profiles for P. Ghezzi

Pietro Ghezzi

Univ Urbino. Emeritus Prof, Brighton & Sussex Med School
Verified email at bsms.ac.uk
Cited by 39264

Clinical relevance of biomarkers of oxidative stress

…, T Grune, HHHW Schmidt, P Ghezzi - Antioxidants & redox …, 2015 - liebertpub.com
Significance: Oxidative stress is considered to be an important component of various diseases.
A vast number of methods have been developed and used in virtually all diseases to …

[HTML][HTML] Erythropoietin as an antiapoptotic, tissue-protective cytokine

P Ghezzi, M Brines - Cell death & differentiation, 2004 - nature.com
Erythropoietin (EPO) increases the number of circulating erythrocytes primarily by preventing
apoptosis of erythroid progenitors. In addition to this proerythroid action, results of recent …

Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach

…, MJ Alcaraz, C Barbas, A Daiber, P Ghezzi… - Pharmacological …, 2018 - ASPET
Systems medicine has a mechanism-based rather than a symptom- or organ-based approach
to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this …

Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress

…, A Cerami, H Ehrenreich, P Ghezzi - Proceedings of the …, 2001 - National Acad Sciences
P < 0.05 indicates statistical significance as compared with control; •, P < 0.05 denotes
statistical significance as compared with EPO during serum withdrawal or kainate treatment.) …

[PDF][PDF] Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment

…, C Toniatti, N Polentarutti, P Fruscella, P Ghezzi… - Immunity, 1997 - cell.com
IL-6 −/− mice showed impaired leukocyte accumulation in subcutaneous air pouches.
Defective leukocyte accumulation was not due to a reduced migratory capacity of IL-6 −/− …

Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury

ML Brines, P Ghezzi, S Keenan… - Proceedings of the …, 2000 - National Acad Sciences
Erythropoietin (EPO), recognized for its central role in erythropoiesis, also mediates neuroprotection
when the recombinant form (r-Hu-EPO) is directly injected into ischemic rodent brain…

Derivatives of erythropoietin that are tissue protective but not erythropoietic

M Leist, P Ghezzi, G Grasso, R Bianchi, P Villa… - Science, 2004 - science.org
Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through interaction
with different receptors. We generated receptor subtype–selective ligands allowing the …

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

…, L Leng, T Kooistra, G Fingerle-Rowson, P Ghezzi… - Nature medicine, 2007 - nature.com
The cytokine macrophage migration inhibitory factor (MIF) plays a critical role in inflammatory
diseases and atherogenesis. We identify the chemokine receptors CXCR2 and CXCR4 as …

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

…, A Leri, P Anversa, P Ghezzi… - Proceedings of the …, 2003 - National Acad Sciences
Erythropoietin (EPO), originally identified for its critical hormonal role in promoting erythrocyte
survival and differentiation, is a member of the large and diverse cytokine superfamily. …

Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis

…, A Cerami, TR Coleman, M Brines, P Ghezzi - The Journal of …, 2003 - rupress.org
P < 0.05; **, P <0.01 versus ischemia plus PBS by Student's t test. Cytokine levels in the
contralateral cortex were below the limit of detection (TNF < 1 U/g tissue; IL-6 < 150 U/g; MCP-1 …